This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by Mallinckrodt Pharmaceuticals.
Reference
Bindra J, et al. Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis. ClinicoEconomics and Outcomes Research : 6 May 2021. Available from: URL: https://doi.org/10.2147/CEOR.S304600
Rights and permissions
About this article
Cite this article
Repository corticotropin injection for active RA: substantial benefits at acceptable cost. PharmacoEcon Outcomes News 879, 23 (2021). https://doi.org/10.1007/s40274-021-7746-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7746-4